Targeted drug combo for children with relapsed blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs (capivasertib and venetoclax) plus a steroid (dexamethasone) in children and young adults with blood cancers that have come back or not responded to treatment. The goal is to see if this drug combination is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and 21 years old.
- Have a blood cancer (such as leukemia or lymphoma) that has come back or not responded to treatment.
- Be able to take oral (by mouth) medications – either swallow tablets or use a feeding tube.
- Have had genetic testing of the tumor (a PI3K/AKT/mTOR change is needed for some parts of the study).
- Have adequate liver, kidney, and heart function.
- Not be pregnant or breastfeeding, and use effective birth control if sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.